Phase III trials evaluating pola-mini-R-CHP (POLAR BEAR Trial, NCT04332822), or the combination of acalabrutinib plus R-mini-CHOP (ARCHED, NCT05820841), over R-mini-CHOP in older patients with DLBCL are currently ongoing. Here, DDIT3 is linked to diffuse large B-cell lymphoma.